Show simple item record

dc.contributor.authorXie, L.
dc.contributor.authorKeshishian, A.
dc.contributor.authorDu, J.
dc.contributor.authorBaşer, Onur
dc.date.accessioned2019-02-28T13:04:26Z
dc.date.accessioned2019-02-28T11:08:15Z
dc.date.available2019-02-28T13:04:26Z
dc.date.available2019-02-28T11:08:15Z
dc.date.issued2015
dc.identifier.citationXie, L., Keshishian, A., Du, J.& Baser, O.(2015). Assessing The Economic Burden And Health Care Resource Utilizations Of Us Medica Re Patients With Myeloproliferative Neoplasms.Value in Health. 18, 3. p.200.
dc.identifier.issn1098-3015
dc.identifier.issn1524-4733
dc.identifier.otherWOS:000354498503180
dc.identifier.urihttp://hdl.handle.net/20.500.11779/633
dc.descriptionOnur Başer (MEF Author)
dc.description.abstractOBJECTIVES: To examine the economic burden and health care resource utilization of myeloproliferative neoplasms (MPNs) in the U.S. Medicare population. METHODS: A retrospective data analysis was performed using the U.S.national Medicare claims from January 2008 through December 2012. MPN patientswere identified using International Classification of Disease 9th Revision ClinicalModification (ICD-9-CM) diagnosis codes 238.4, 238.71, 238.76 and 289.83. The diagnosis date was designated as the index date. A comparison cohort without a MPNdiagnosis was created for patients of the same age, region, gender, index year andbaseline Charlson Comorbidity Index score. A random index date was chosen forthe comparison cohort to reduce selection bias. Patients were required to havecontinuous medical and pharmacy benefits 1 year pre- and post-index date. Oneto-one propensity score matching (PSM) was performed to compare follow-uphealth care costs and utilizations between the cohorts, adjusting for demographicand clinical characteristics. RESULTS: Eligible patients (N=17,950) were identifiedfor the MPN and comparison cohorts. After 1:1 PSM, a total of 5,546 patients werematched from each cohort and baseline characteristics were well-balanced. MPNpatients had a higher percentage of health care resource utilizations, includingMedicare carrier (98.6% vs. 65.9%), Durable Medical Equipment (DME; 29.5% vs.14.4%), Home Health Agency (HHA; 12.4% vs. 5.0%), outpatient visits (76.6% vs.37.4%), inpatient hospitalizations (27.2% vs. 6.8%) and Skilled Nursing Facility (SNF;7.5% vs. 2.0%) visits than non-MPN patients. Patients diagnosed with MPNs alsoincurred significantly higher costs, including Medicare carrier ($3,872 vs. $1,283),DME ($266 vs. $91), HHA ($639 vs. $250), outpatient ($10,061 vs. $3,204), inpatient($5,449 vs. $1,054), pharmacy ($1,069 vs. $713) and total health care costs ($23,060vs. $7,076; p<0.0001). CONCLUSIONS: MPN patients had a higher burden of illnesscompared to non-MPN patients.
dc.language.isoeng
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titlePCN62 - Assessing the economic burden and health care resource utilizations of us medica re patients with myeloproliferative neoplasms
dc.typeconferenceObject
dc.relation.journalValue in Health
dc.contributor.departmentMEF Üniversitesi, İİSBF, Ekonomi Bölümü
dc.identifier.volume18
dc.identifier.issue3
dc.identifier.startpage200
dc.identifier.endpage200
dc.relation.publicationcategoryUluslararası Yayın


Files in this item

This item appears in the following Collection(s)

Show simple item record